Cargando…

655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection

BACKGROUND: Treatment for first recurrent Clostridioides difficile infection (frCDI) or multiply recurrent CDI (mrCDI) is complex and may include antibiotics, monoclonal antibodies, or fecal transplantation. Improved understanding of rCDI pathogenesis can help guide treatment. We report microbiome f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelly, Colleen R, Kraft, Colleen S, Straub, Tim, Litcofsky, Kevin, Wortman, Jennifer R, Cohen, Stuart H, Berenson, Charles, McGovern, Barbara, Hasson, Brooke, Hot, Dina, Pardi, Darrell, Ford, Christopher, Henn, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679316/ http://dx.doi.org/10.1093/ofid/ofad500.718

Ejemplares similares

Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection
por: McGovern, Barbara, et al.
Publicado: (2021)

653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection
por: Cohen, Stuart, et al.
Publicado: (2022)

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
por: Sims, Matthew D., et al.
Publicado: (2023)

1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes
por: Ford, Christopher, et al.
Publicado: (2018)

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
por: McGovern, Barbara H, et al.
Publicado: (2020)

621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner
por: Henn, Matthew, et al.
Publicado: (2018)

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
por: Khanna, Sahil, et al.
Publicado: (2022)

Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
por: Henn, Matthew, et al.
Publicado: (2017)

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial
por: Garey, Kevin W., et al.
Publicado: (2023)

Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI
por: Sims, Matthew, et al.
Publicado: (2023)

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic
por: Berenson, Charles S, et al.
Publicado: (2023)

1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI)
por: Ford, Christopher, et al.
Publicado: (2019)

658. Diagnostic Testing Among Patients with Suspected Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III a Phase 3 Clinical Trial: Implications for Clinical Practice vs Clinical Trials
por: Sims, Matthew, et al.
Publicado: (2021)

2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Saha, Srishti, et al.
Publicado: (2019)

Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
por: McChalicher, Christopher, et al.
Publicado: (2022)

Resolution rates in clinical trials for microbiota restoration for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2023)

389. Epidemiology of Multiple Recurrent Clostridioides difficile in the Atlanta Metropolitan Area between 2016 and 2019
por: Fridkin, Scott, et al.
Publicado: (2022)

109. Differences in Gram-Negative Antibiotic Susceptibility Among Patients Receiving Fecal Microbiota Transplant for Clostridioides difficile
por: Woodworth, Michael, et al.
Publicado: (2018)

19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial
por: Hohmann, Elizabeth, et al.
Publicado: (2021)

1496. Bezlotoxumab Administered at the End of a Suppressive Drug Regimen for Patients with Multiply Recurrent Clostridioides difficile Infection
por: Tan, Xing, et al.
Publicado: (2019)

Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
por: Steed, Danielle Barrios, et al.
Publicado: (2020)

Multiply Recurrent Episodes of Gastric Emphysema
por: Pauli, Eric M., et al.
Publicado: (2011)

The interplay of SARS-CoV-2 and Clostridioides difficile infection
por: Khanna, Sahil, et al.
Publicado: (2021)

Kinetics of polymerase chain reaction positivity in patients with Clostridioides difficile infection
por: Saha, Srishti, et al.
Publicado: (2021)

Incidence of Clostridioides difficile infection in peripartum women: a retrospective cohort study
por: Saha, Srishti, et al.
Publicado: (2020)

Effect of peripartum Clostridioides difficile infection on pregnancy and neonatal outcomes: an observational study
por: Saha, Srishti, et al.
Publicado: (2023)

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
por: Khanna, Sahil, et al.
Publicado: (2020)

1035. Manufacturing Processes of SER-109, a Purified Investigational Microbiome Therapeutic, Reduce Risk of Transmission of Emerging and Undetected Infections in Donor Stool
por: McChalicher, Christopher, et al.
Publicado: (2021)

Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection
por: Normington, Charmaine, et al.
Publicado: (2021)

A268 RESOLUTION RATES IN OPEN-LABEL VERSUS RANDOMIZED CONTROLLED TRIALS FOR MICROBIOTA RESTORATION FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: AN UPDATED META-ANALYSIS
por: Tariq, R, et al.
Publicado: (2023)

ODP655 Apathetic Hyperthyroidism
por: Seetharaman, Kavita
Publicado: (2022)

Gut metabolites predict Clostridioides difficile recurrence
por: Dawkins, Jennifer J., et al.
Publicado: (2022)

Recurrent hypoglycemia and a slowly rising hemidiaphragm: A case report
por: Simpson, Vincent, et al.
Publicado: (2021)

Microbiota in Clostridioides difficile-Associated Diarrhea: Comparison in Recurrent and Non-Recurrent Infections
por: Gazzola, Alessandra, et al.
Publicado: (2020)

Outcomes in Patients with SARS-CoV-2 and Clostridioides difficile Coinfection
por: Sehgal, Kanika, et al.
Publicado: (2021)

Novel risk factors and outcomes in inflammatory bowel disease patients with Clostridioides difficile infection
por: Voth, Elida, et al.
Publicado: (2021)

Multiply Recurrent Composite Hemangioendothelioma of Penis with Histologic Progression to High-Grade Features
por: Bui, Chau M., et al.
Publicado: (2023)

Risk Factors Associated with Recurrent Clostridioides difficile Infection
por: Negrut, Nicoleta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5u3ak252gg6v2jr8ha630d8ofe